Synairgen Share Discussion Threads

[cfccfc1970] 05/4/2020 14:06

Apologies for my ignorance but is SNG working with Gilead as they have Remdesivir in a clinical trial but just announced a significant ramp up in production, though trial continues.
Mentioned just in case relevant.

[nobbygnome] 05/4/2020 14:00

His apparent confidence had not escaped me and is very encouraging!

[likya123] 05/4/2020 13:52

Thanks Nobby.

He sounds very confident, i wonder why and sounds like he has already planned how to make it available globally. No wonder they're spending £4 million on sng001!

Not if but "when"....

'when we have the results we will discuss appropriate routes to expeditious approval with regulators and other interested parties around the world. This, we believe, is the fastest cleanest route to making SNG001 globally available'

[lunus1] 05/4/2020 13:51

Nobby thanks for the update. Although disappointing I note his positivity in taking things forward after the trial. He sounds confident this will make a difference.

[awise355] 05/4/2020 13:44

That's a shame - someone with an account needs to tell the guys in LSE the news.

[nobbygnome] 05/4/2020 13:39

I emailed Richard Marsden (Synairgen CEO) yesterday about the Recovery trial and he was good enough to reply. Please see the paragraph below which confirms that SNG001 is only in the SG016 trial so our speculation last evening was denitely wrong. Interestingly he talks about expeditious approval.

'SNG001 is only being tested in the SG016 placebo-controlled trial, when we have the results we will discuss appropriate routes to expeditious approval with regulators and other interested parties around the world. This, we believe, is the fastest cleanest route to making SNG001 globally available.'

[hazl] 05/4/2020 13:27

useful background...not SNG but respirators protective clothing..

Ric Gillams
@RicGillams
Replying to
@ib9994
and
@profrobread
Thank you for the interest. We hope to get details public soon. Part of our aim is to make manufacture quick and easy to encourage widespread adoption. PM me and I can try to keep you on the loop when we have news. Will be keeping website up to date:
1:29 PM · Mar 29, 2020·Twitter for Android

[hazl] 05/4/2020 13:22

'. our first two Covid-19 “victims”; were two pneumococcal septic shock in patients not seen by their private doctors because of Covid-19 fear and lack of PPE - kind of...'

FROM ABOVE....
Some interesting charts retweeted from 'Eric Topol.'

[jambam] 05/4/2020 13:16

Agree on 1,3,4. As for point 2 who knows but the pace of developments is unprecedented

[likya123] 05/4/2020 13:06

makendon, great input and I do think we're in for a very good day tomorrow for 4 main reasons.

1. Start of new tax year tomorrow and I aswell as hundreds of others will be using their £20k isa allowance all in Synairgen.

2. This global unblinded recovery trial looks like it will have to be RNSd (i believe the only reason for the slight confusion is that the original documents have been updated due the fast moving unprecedented situation and Synairgen has only been included in the last few days).

3. The seller looks to be finished or very near finished plus from a technical view point we filled the gap around 47p before close on Friday.

4. No ramping but I'm now more convinced than ever that Synairgen already know they'll succeed and are just getting the confirmation necessary.

This would therefore be life changing in more ways than one!

Enjoy the beautiful weather and stay safe.

[torreskid] 05/4/2020 13:06

Confused!

Why mention If-b and then state not currently used in this trial!!!

When will it be included?

Also, I said before that it theoretically could be beneficial as part of combination therapy with the other three options

[makendon] 05/4/2020 12:23

It’s worth noting though, the document in the link below, from the CMO states:

Hxxps://www.recoverytrial.net/files/professional-downloads/the-importance-of-covid-19-clinical-trials.pdf

Dear colleagues,
Novel Coronavirus: Clinical Trials
We are writing to ask that every effort is made to enrol COVID-19 patients in the national priority clinical trials; there are trials in primary care, hospital settings and ICUs.
As yet, there are no proven treatments for Covid-19. We need to gather reliable evidence through clinical trials. Using international evidence and UK expertise the most promising potential treatments, at this stage, have been identified and the UK is running national clinical trials to gather evidence across the whole disease spectrum.
The key three national trials are:
PRINCIPLE (higher risk patients in primary care trial). www.principletrial.org
RECOVERY (in hospital trial) For further information please email: [e-mail]
REMAP-CAP (critically ill patient trial) For further information please email: [e-mail]
Other priority studies, including observational studies, are listed here
hxxps://www.nihr.ac.uk/covid-19/urgent-public-health-studies-covid-19.htm
These trials are being run as simply as they can to reduce the burden on the NHS, with adaptive designs so further treatments can be added if new promising candidates are identified. The results are essential to the future treatment of UK and global patients. We will ensure important results are disseminated rapidly to improve practice.
The faster that patients are recruited, the sooner we will get reliable results. While it is for every individual clinician to make prescribing decisions, we strongly discourage the use of off-licence treatments outside of a trial, where participation in a trial is possible. Use of treatments outside of a trial, where participation was possible, is a wasted opportunity to create information that will benefit others. The evidence will be used to inform treatment decisions and benefit patients in the immediate future.

This links directly to NIHR, which

hxxps://www.nihr.ac.uk/covid-19/urgent-public-health-studies-covid-19

Where the very first study in the list is:

A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection

Is that not enough to convince people this is a live & sanctioned trial of SNG001?

[makendon] 05/4/2020 12:13

Thanks Hazl,

It’s a really good article written by The Times Business reporter Sabah Meddings, her credentials speak for themselves :)

Bio:
Sabah Meddings is a business reporter at the Sunday Times, focusing primarily on pharmaceuticals and biotech, along with consumer goods and leisure. She has spent the past year investigating Britain's biggest gambling companies, digging around in private healthcare companies working for the NHS, and probing the investments of fund manager Neil Woodford.

Prior to the Sunday Times, Sabah was a City correspondent at the Daily Mail, where she wrote across all sectors. Sabah has a degree in international relations and politics from the University of Aberdeen. Her background is in local journalism, having started her career at the Eastern Daily Press in Norfolk.

[nobbygnome] 05/4/2020 12:08

Sadly I agree.

Likewise I am very lucky to have a big garden and am off to tackle the ivy which is threatening to take over the world!

[toffeeman] 05/4/2020 12:02

RECOVERY TRIAL

1. the website states (hxxps://www.recoverytrial.net/) accessed 11.54 April 5th

The RECOVERY Trial will begin by testing some of these suggested treatments:

*Lopinavir-Ritonavir (commonly used to treat HIV)
*Low-dose Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation).
*Hydroxychloroquine (related to an anti-malarial drug)
*Inhaled interferon-beta1a (an antiviral drug; not currently in use in this trial)

The Recovery Protocol (see hxxps://www.recoverytrial.net/files/professional-downloads/recovery-protocol-v2-0-2020-03-23.pdf)

published on March 23rd states on P7:

Arm 3: Interferon--1a. Nebulized solution of IFN-β1a 6MIU (0.5ml of a solution containing 12MIU/ml) once-daily for 10 days or until discharge.

Possible interpretations:

1. The home page of the Recovery trial is out of date
2. The protocol has been updated (I can't find v1) to include SNG001
3. The market has missed either of these interpretations.

My conclusion:

It's all in the price and tomorrow will not see a dramatic rise (I do of course hope I am wrong)

I have a garden, I realise I am lucky, off to do some weeding.

[hazl] 05/4/2020 11:46

a reminder....a week ago

[d1nga] 05/4/2020 09:27

2449, and so it begins again

Lol

[fatnacker] 05/4/2020 08:54

we need a leak or two, they wont be able to keep a lid on if dosed patients make good progress, hopefully.

[nobbygnome] 05/4/2020 08:53

>> 801

That is part of the reason they raised money so that they could make more drug. That makes perfect sense to me. Yes the money might be wasted but at least the money was raised at a decent market cap. After all 2 months ago the price was under 10p!

[hazl] 05/4/2020 08:51

Well though thee S Times mentioned us last week,disappointing that AH didn't mention us in the larger piece this week.

[801710245] 05/4/2020 08:51

It's a bit of a dilemma - having to 'spend big' manufacturing countless batches of a drug than may not be approved - against waiting for approval and not having the supply 'ready to go'.

It's another binary conundrum.

[nobbygnome] 05/4/2020 08:40

Well if I was suffering from pneumonia, I would definitely want to take it, regulatory approval or not. I am sure that would apply to most people if you summarised in simple terms what is known about the drug. Sadly regulatory authorities are unlikely to agree to that but you never know that may change if it gets really bad in hospitals. Anyway I guess at the moment they don't have many doses available to treat patients not in the trial and probably are in the process of making a lot more. The demand will be enormous if and when the trial result is positive so they must be making some big batches now.

[801710245] 05/4/2020 08:19

Under sub-section '1.3' of mdchand's post '2372', it sets a scenario where 2million hospital admissions would stretch the NHS resources to such an extent that treatment with only a limited effect, might be considered.

Is this to suggest that during the next month, the situation may become so acutely desperate, that SNG001 might be given as a treatment without a proper - or complete - assessment of efficacy?